Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2659-2670

  Hoshiko, Shinri ^a   Kawaguchi, Makiko ^a   Fukushima, Tsuyoshi ^a   Haruyama, Yukihiro ^a   Yorita, Kenji ^a   Tanaka, Hiroyuki ^a   Seiki, Motoharu ^b   Inatsu, Haruhiko ^a   Kitamura, Kazuo ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CLAUDIN 2; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR TYPE 1; SERINE PROTEASE INHIBITOR KUNITZ TYPE 1; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COLON CARCINOGENESIS; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; IMMUNOREACTIVITY; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; INTESTINE TUMOR; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SERINE PROTEASE INHIBITOR KUNITZ TYPE 1 GENE; SIGNAL TRANSDUCTION; SURVIVAL TIME; UPREGULATION; WILD TYPE;

ANIMALS; CARCINOGENS; CELL LINE, TUMOR; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; GENE DELETION; GENE EXPRESSION PROFILING; HEPATOCYTE GROWTH FACTOR; INTESTINAL MUCOSA; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PERMEABILITY; TUMOR SUPPRESSOR PROTEINS; WNT SIGNALING PATHWAY;

EID: 84876915973     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3337     Document Type: Article

References (49)

1. Turner Jr. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9:799-809.
2. Turksen K, Troy TC. Junctions gone bad: Claudins and loss of the barrier in cancer. Biochim Biophys Acta 2011;1816:73-9.
3. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009;175:1453-63.
4. Buzza MS, Netzel-Arnett S, Shea-Donohue T, Zhao A, Lin CY, List K, et al. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A 2010;107:4200-5.
5. Netzel-Arnett S, Buzza MS, Shea-Donohue T, Desilets A, Leduc R, Fasano A, et al. Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis 2012; 18:1303-14.
6. Antalis TM, Bugge TH,WuQ. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011;99:1-50.
7. Nagaike K, Kawaguchi M, Takeda N, Fukushima T, Sawaguchi A, Kohama K, et al. Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice.AmJ Pathol 2008;173:1464-75.
8. Kawaguchi M, Takeda N, Hoshiko S, Yorita K, Baba T, Sawaguchi A, et al. Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity. Am J Pathol 2011;179: 1815-26.
9. Heinz-Erian P, Muller T, Krabichler B, Schranz M, Becker C, Ruschendorf F, et al. Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am J Hum Genet 2009;84:188-96.
10. Miller GS, List K. The matriptase-prostasin proteolytic cascade in epithelial development and pathology. Cell Tissue Res 2013;351: 245-53
11. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003;22: 223-36.
12. Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N, Nabeshima K, et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization ofHAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999;47: 673-82.
13. Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): Pathophysiological functions in vivo. FEBS J 2010;277:2230-7.
14. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999;274:18237-42.
15. Oberst MD, Chen LY, Kiyomiya K, Williams CA, Lee MS, Johnson MD, et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 2005; 289:C462-70.
16. List K, Bugge TH, Szabo R. Matriptase: Potent proteolysis on the cell surface. Mol Med 2006;12:1-7.
17. Szabo R, Kosa P, List K, Bugge TH. Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Am J Pathol 2009;174:2015-22.
18. Hashimoto T, Kato M, Shimomura T, Kitamura N. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J 2010;277:4888-900.
19. Kato M, Hashimoto T, Shimomura T, Kataoka H, Ohi H, Kitamura N. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. J Biochem (Tokyo) 2012;151:179-87.
20. Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res 2009;69:1828-35.
21. Tanaka H, Nagaike K, Takeda N, Itoh H, Kohama K, Fukushima T, et al. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol 2005;25:5687-98.
22. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: A tale of two sides or a continuum? Gut 2012;61:794-7.
23. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 2000;60:6148-59.
24. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfateinduced colon carcinogenesis in mice. Carcinogenesis 2006;27:162-9.
25. Nagaike K, Kohama K, Uchiyama S, Tanaka H, Chijiiwa K, Itoh H, et al. Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci 2004;95:728-35.
26. Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 2004;95:803-8.
27. Baba T, Kawaguchi M, Fukushima T, Sato Y, Orikawa H, Yorita K, et al. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness. J Pathol 2012;228: 181-92.
28. Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, et al. Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 2007;67:4311-9.
29. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000;275:40453-62.
30. Domoto T, Takino T, Guo L, Sato H. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase. Cancer Sci 2012;103:448-54.
31. Wali RK, Roy HK, Kim YL, Liu Y, Koetsier JL, Kunte DP, et al. Increased microvascular blood content is an early event in colon carcinogenesis. Gut 2005;54:654-60.
32. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129.
33. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/ Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
34. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006;442:779-85.
35. Kataoka H, Uchino H, Denda K, Kitamura N, Itoh H, Tsubouchi H, et al. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa. Cancer Lett 1998;128:219-27.
36. Seshargiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488:660-4.
37. Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, et al. Claudin-2 expression increases tumorigenicity of colon cancer cells: Role of epidermal growth factor receptor activation. Oncogene 2011;30:3234-47.
38. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 2012;12: 89-103.
39. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-76.
40. Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis 2012;33:1142-8.
41. Angus-Hill ML, Elbert KM, Hidalgo J, Capecchi MR. T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. Proc Natl Acad Sci U S A 2011;108:4914-9.
42. Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, et al. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology 2009; 137:1346-57.
43. Takahashi M, Fujita M, Furukawa Y, Hamamoto R, Shimokawa T, Miwa N, et al. Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis. Cancer Res 2002;62:5651-6.
44. Vogel LK, Saebo M, Skjelbred CF, Abell K, Pedersen ED, Vogel U, et al. The ratio of matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 2006;6:176.
45. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, et al. Tumor detection by imaging proteolytic activity. Cancer Res 2010;70:1505-12.
46. Kosa P, Szabo R, Molinolo AA, Bugge TH. Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Oncogene 2012;31:3679-95.
47. Godiksen S, Selzer-Plon J, Pedersen ED, Abell K, Rasmussen HB, Szabo R, et al. Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary. Biochem J 2008;413:251-9.
48. Hirota CL, Moreau F, Iablokov V, Dicay M, Renaux B, Hollenberg MD, et al. Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012;303: G111-9.
49. Jung H, Lee KP, Park SJ, Park JH, Jang YS, Choi SY, et al. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene 2008;27: 2635-47.